+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Generic COVID-19 drug priced at ₹5,400 per vial by Hyderabad-based Hetero

Jun 25, 2020, 09:01 IST
IANS
Picture shown is for illustration purpose onlyUnsplash
Covifor, the generic version of Covid-19 drug Remdesivir, will be available in India for Rs 5,400 per 100 mg vial, Hyderabad-based Hetero Labs announced on Wednesday.
Advertisement

Following the approval to Covifor by the Drug Controller General of India , Hetero Healthcare Ltd, a group company of Hetero, announced that it is set to deliver the first set of 20,000 vials.

They will be made available in two equal lots of 10,000 each. One lot will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra while the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Thiruvananthapuram and Goa within a week to meet the emergency requirements, the company said.

"Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating Covid-19 infection rates. We are working closely with the government and medical community to make Covifor quickly accessible to both public and private healthcare settings across the country," said M. Srinivasa Reddy, Managing Director, Hetero Healthcare.

Covifor is the first generic brand of Remdesivir which is indicated for the treatment of Covid-19 patients in adults and children, hospitalised with severe symptoms of the disease. The drug is available in 100 mg vial (injectable). It needs to be administered intravenously in a hospital, or critical care setting, under the supervision of a registered medical practitioner.

Advertisement

Covifor is anticipated to play a significant role in bringing down the mortality rates caused by Covid-19, given its proven positive clinical outcomes, the company added.

SEE ALSO: Coronavirus cases in India state wise
Coronavirus News and Updates

You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article